FDA
-
-
-
-
-
-
-
'We are incrementally positive on Scholar Rock (SRRK) Shares'; PT Raised at Piper Sandler
-
-
-
-
-
-
-
Scholar Rock targets 2026 apitegromab BLA resubmission and launch
-
-
-
-
-
-
-
Scholar Rock (SRRK) PT Lowered to $44 at H.C. Wainwright
-
-
-
-
-
-
-
Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment
-
-
-
-
-
-
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
-
-
-
-
-
-
Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
-
-
-
-
-
-
-
Scholar Rock Holding Corp. (SRRK) Highlights 2025 Strategic Priorities
-
322,090 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

